New drug approvals in acute myeloid leukemia: what's the best end point? - Wikidata - awgldk - TriplyDB

New drug approvals in acute myeloid leukemia: what's the best end point?

New drug approvals in acute myeloid leukemia: what's the best end point?

http://www.wikidata.org/entity/Q42637732

about

Measurable residual disease testing in acute myeloid leukaemia.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials.Acute myeloid leukemia: 2016 Update on risk-stratification and management.Acute Myeloid Leukemia: How Do We Measure Success?Leukemic stem cells: identification and clinical application.Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.

P2860

Q30234914-5764BA1E-F56D-4E7D-B67B-15BB76224290 Q37624593-1D0545E5-1A8F-451D-9F14-168ABEE67C3F Q38642017-C3ED16D1-C5A4-42C4-98AE-E8BD2D904CAD Q38897289-F182FB2D-090F-4991-B0C9-763B331B0B4B Q38948650-22BEC622-6EFE-4EE6-8C4A-DD12EA5B6276 Q39208298-949656A6-7340-4FA0-B7BF-72D3F80AFFDE Q51773142-B6230D1B-EE43-4D48-985A-B821CF7C17DF

P2860

New drug approvals in acute myeloid leukemia: what's the best end point?

http://www.wikidata.org/entity/Q42637732

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

New drug approvals in acute myeloid leukemia: what's the best end point?

@en

New drug approvals in acute myeloid leukemia: what's the best end point?

@nl

type

label

New drug approvals in acute myeloid leukemia: what's the best end point?

@en

New drug approvals in acute myeloid leukemia: what's the best end point?

@nl

prefLabel

New drug approvals in acute myeloid leukemia: what's the best end point?

@en

New drug approvals in acute myeloid leukemia: what's the best end point?

@nl

P1433

Q42637732-CB923A0F-4B0B-424A-BA86-8DB200DBFFDE

P1476

Q42637732-EA871EF3-CDB2-4649-902B-9F35A9518FEE

P2093

Q42637732-06C83848-5740-45AC-94BE-22DFFA9B934F

Q42637732-7801DBAA-4EA9-4F08-AF1A-20CBF9C00D7B

Q42637732-95B76ACC-4BFF-4E2E-8B95-4414F5FC241B

Q42637732-A5CAF6ED-7D08-4463-B79C-1B38F51D6626

P2860

Q42637732-03B7AFA5-A452-4DD3-86B0-146F4F64BE05

Q42637732-131F53CE-FE50-4389-B757-E115F8F83A63

Q42637732-15EF3EDB-92C7-45E4-99F7-7242D543BFD7

Q42637732-1D6380DC-C005-4C4F-A31B-E1EF25D09A03

Q42637732-3C29FB5B-B362-4922-8EE2-5530574042EF

Q42637732-3C636129-CF8F-4822-ADF3-1246A4E1F743

Q42637732-48DDAEF4-B454-4362-AA49-A442ED831D77

Q42637732-4ED686CD-F919-43C1-AF54-354C05DE3400

Q42637732-5FC7CFCA-C502-4220-8DA6-DA77CB849363

Q42637732-81814144-4E11-436E-8588-35BE9378C4CB

P2888

Q42637732-E9FC7424-17A3-4BD6-82A4-D3A9309F65A9

P304

Q42637732-CE9CF0F9-3BF3-47F3-BF6C-8C778F154159

P31

Q42637732-0B734DFC-1938-4A05-9DBB-B07AC4D75D76

Q42637732-2139cfbd-72d1-48a5-98ff-641db4db12b2

P356

Q42637732-5F24D445-E5B0-4DB8-85B9-299D8792C94F

P433

Q42637732-0C259238-7270-47EC-B8CC-ACDA02458C20

P478

Q42637732-E880BDB7-5D9D-4848-870B-6E053D05AA7F

P50

Q42637732-33976C4E-6A16-4F5C-9849-508BD1ABF14E

P577

Q42637732-560A7A31-474C-4539-9430-149E95593C60

P5875

Q42637732-47A35431-BEFF-4DBA-AA7C-A379C4F234F6

P6179

Q42637732-949880F3-7BC9-4B67-BBC0-AC85E1ACE33F

P698

Q42637732-42D15D14-3872-442D-89A2-F39368C7E066

P921

Q42637732-5FA22958-5BA0-4CFB-B8DD-EB4B7DB9FCDF

P932

Q42637732-0EE30010-DF14-40D6-8CCD-6214387A3455

P356

P1433

P1476

New drug approvals in acute myeloid leukemia: what's the best end point?

@en

P2093

E Estey

http://www.w3.org/2001/XMLSchema#string

M Othus

http://www.w3.org/2001/XMLSchema#string

R P Gale

http://www.w3.org/2001/XMLSchema#string

S J Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study

Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

High-dose daunorubicin in older patients with acute myeloid leukemia.

Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.

Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.

Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia

P2888

P304

521-525

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2015.262

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

30

http://www.w3.org/2001/XMLSchema#string

P50

Frederick R. Appelbaum

P577

2015-12-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

287327031

http://www.w3.org/2001/XMLSchema#string

P6179

1024797456

http://www.w3.org/2001/XMLSchema#string

P698

26677969

http://www.w3.org/2001/XMLSchema#string

P921

P932

4777773

http://www.w3.org/2001/XMLSchema#string